• LAST PRICE
    1.2000
  • TODAY'S CHANGE (%)
    Trending Up0.0200 (1.6949%)
  • Bid / Lots
    1.1900/ 12
  • Ask / Lots
    1.2000/ 1
  • Open / Previous Close
    1.2500 / 1.1800
  • Day Range
    Low 1.1800
    High 1.3500
  • 52 Week Range
    Low 0.7900
    High 4.3799
  • Volume
    213,164
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.18
TimeVolumeEQ
09:32 ET213891.23
09:33 ET66261.2501
09:35 ET23021.25
09:39 ET25001.241
09:44 ET7501.26
09:46 ET15001.28
09:48 ET71341.27
09:50 ET40001.27
09:51 ET191061.28
09:53 ET66061.31
09:55 ET29101.31
09:57 ET57541.305
10:00 ET3801.31
10:04 ET11251.3
10:06 ET1651.315
10:08 ET90231.2893
10:09 ET6501.2747
10:13 ET5001.2701
10:15 ET30001.272
10:18 ET133001.28
10:20 ET18001.28
10:24 ET2001.27
10:26 ET21001.26
10:27 ET6751.2498
10:29 ET10001.2499
10:33 ET10001.2142
10:38 ET3331.2471
10:42 ET7851.2499
10:45 ET12671.23
10:47 ET148001.1969
10:49 ET29001.199
10:51 ET19001.2
10:54 ET51001.1999
10:56 ET2501.2242
10:58 ET4001.215
11:00 ET6701.23
11:02 ET21001.225
11:05 ET26321.2001
11:09 ET1001.2001
11:14 ET12571.2
11:20 ET13031.2278
11:21 ET61911.22
11:23 ET6501.1984
11:30 ET5001.1805
11:32 ET2001.19
11:34 ET3361.1899
11:36 ET8221.19
11:38 ET19001.19
11:43 ET30301.205
11:45 ET15001.1901
11:48 ET10001.1913
11:52 ET14001.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEQ
Equillium Inc
40.5M
-0.5x
---
United StatesMBRX
Moleculin Biotech Inc
35.5M
-1.4x
---
United StatesSIOX
Sio Gene Therapies Inc
33.1M
-0.7x
---
United StatesCVKD
Cadrenal Therapeutics Inc
32.9M
0.0x
---
United StatesCOEP
Coeptis Therapeutics Holdings Inc
32.3M
12.9x
---
United StatesODTC
Odonate Therapeutics Inc
48.6M
-0.6x
---
As of 2023-02-02

Company Information

Equillium, Inc. is a clinical-stage biotechnology company develops novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The Company’s initial product candidate, itolizumab (EQ001), is a clinical-stage monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The Company’s pipeline is focused on developing EQ001, EQ101 and EQ102 disease modifying treatments for multiple severe immuno-inflammatory disorders. Its clinical development programs for EQ001 for the treatment of acute graft-versus-host disease (aGVHD) and lupus/lupus nephritis. The Company is in the process of clinical development of EQ101 and EQ102 and to initiate a Phase II study of EQ101 in alopecia areata and a Phase I study of EQ102 in celiac disease. The Company is conducting the EQUATE study, is a Phase Ib clinical study of EQ001 therapy concomitant with steroids for the treatment of aGVHD.

Contact Information

Headquarters
2223 Avenida de La Playa Ste 105LA JOLLA, CA, United States 92037-3217
Phone
858-412-5302
Fax
302-636-5454

Executives

Executive Chairman of the Board
Daniel Bradbury
President, Chief Executive Officer, Director
Bruce Steel
Chief Financial Officer
Jason Keyes
Chief Operating Officer, Senior Vice President
Christine Zedelmayer
Chief Scientific Officer, Director
Stephen Connelly

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$40.5M
Revenue (TTM)
$0.00
Shares Outstanding
34.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.22
EPS
$-2.34
Book Value
$2.26
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.